Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

Cited by (1,002)

Items 601–700 of 1,002

1. A pyroptosis-related lncRNA signature predicts prognosis and immune microenvironment in head and neck squamous cell carcinoma
   Wenying Zhu, Zhipeng Ye, Ling Chen, Haifeng Liang, Qian Cai · 2021 · International Immunopharmacology
2. Evolution and modulation of antigen-specific T cell responses in melanoma patients
   Jani Huuhtanen, Liang Chen, Emmi Jokinen, Henna H.E. Kasanen, Tapio Lönnberg, Anna S. Kreutzman, Katriina Johanna Peltola, Micaela Hernberg, Chunlin Wang, Cassian Yee et al. · 2022 · Nature Communications
3. PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models
   Chun Wai Wong, Christos Evangelou, Kieran N. Sefton, Rotem Leshem, Wei Zhang, Vishaka Gopalan, Sorayut Chattrakarn, Macarena Lucia Fernandez Carro, Erez Uzuner, Holly Mole et al. · 2023 · Nature Communications
4. Cancer immunophenotyping by seven‐colour multispectral imaging without tyramide signal amplification
   Marieke E. Ijsselsteijn, Thomas P. Brouwer, Ziena Abdulrahman, Eileen Reidy, Ana Ramalheiro, Anne Marijne Heeren, Alexander L. Vahrmeijer, Ekaterina S. Jordanova, Noel F.C.C. de Miranda · 2018 · The Journal of Pathology Clinical Research
5. The aberrant expression of rhythm genes affects the genome instability and regulates the cancer immunity in pan‐cancer
   Jian Zhou, Xia Li, Minghui Zhang, Jinan Gong, Qi Li, Baocong Shan, Tianzhen Wang, Tongsen Zheng, Tongsen Zheng, Xiaobo Li · 2020 · Cancer Medicine
6. Computing Skin Cutaneous Melanoma Outcome From the HLA-Alleles and Clinical Characteristics
   Anjali Dhall, Sumeet Patiyal, Harpreet Kaur, Sherry Bhalla, Chakit Arora, Gajendra P. S. Raghava · 2020 · Frontiers in Genetics
7. Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade
   Chi Wing Yan, Nabil Saleh, Jinming Yang, Caroline A. Nebhan, Anna E. Vilgelm, E. Premkumar Reddy, Joseph T. Roland, Douglas Buckner Johnson, Sheau‐Chiann Chen, Rebecca L. Shattuck-Brandt et al. · 2021 · Molecular Cancer
8. B3GALT4 remodels the tumor microenvironment through GD2-mediated lipid raft formation and the c-met/AKT/mTOR/IRF-1 axis in neuroblastoma
   Yongliang Sha, Yun Liu, Jiaxing Yang, Yangyang Wang, Baocheng Gong, Yan Jin, Tong-Yuan Qu, Fan-Tong Xia, Lei Han, Qiang Zhao · 2022 · Journal of Experimental & Clinical Cancer Research
9. Krüppel-like factor 4 regulates the cytolytic effector function of exhausted CD8 T cells
   Jinwoo Nah, Rho Hyun Seong · 2022 · Science Advances
10. Lipid droplets are a metabolic vulnerability in melanoma
    Dianne Lumaquin, Emily D. Montal, Eleanor Johns, Arianna Baggiolini, Ting Hsiang Huang, Yilun Ma, Charlotte LaPlante, Shruthy Suresh, Lorenz Studer, Richard Mark White · 2023 · Nature Communications
11. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance
    Yaqi Li, Jing Liu, Long Gao, Yuan Liu, Fang Meng, Xiaoan Li, Frank Xiao-Feng Qin · 2019 · Immunology Letters
12. Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence
    Wiebke Pruessmann, Julie A. Rytlewski, James S. Wilmott, Martín C. Mihm, Grace Heloise Attrill, Beatrice Dyring‐Andersen, Paul Fields, Qian Zhan, Andrew J. Colebatch, Peter M. Ferguson et al. · 2020 · Nature Cancer
13. Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non–small Cell Lung Cancer
    Yusuke Inoue, Katsuhiro Yoshimura, Koji Nishimoto, Naoki Inui, Masato Karayama, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa et al. · 2020 · JAMA Network Open
14. Systems biology analysis identifies TNFRSF9 as a functional marker of tumor-infiltrating regulatory T-cell enabling clinical outcome prediction in lung cancer
    Jae-Won Cho, Jimin Son, Sang‐Jun Ha, Insuk Lee · 2021 · Computational and Structural Biotechnology Journal
15. Identification of 15 lncRNAs Signature for Predicting Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1 Monotherapy
    Jian‐Guo Zhou, Bo Liang, Jianguo Liu, Su‐Han Jin, Sisi He, Benjamin Frey, Ning Gu, Rainer Fietkau, Markus Hecht, Hu Ma et al. · 2021 · Cells
16. Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma
    Samuel S. Freeman, Moshe Sade-Feldman, Jaegil Kim, Chip Stewart, Anna L. K. Gonye, Arvind Ravi, Monica B. Arniella, Irena Gushterova, Thomas James LaSalle, Emily M. Blaum et al. · 2022 · Cell Reports Medicine
17. KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas
    Gu, Meichen, Gao, Yanli, Chang, Pengyu · 2021 · Cancers
18. PUREE: accurate pan-cancer tumor purity estimation from gene expression data
    Egor Revkov, Tanmay Kulshrestha, Ken Wing-Kin Sung, Anders J. Skanderup · 2023 · Communications Biology
19. Targeting Proteasomes and the MHC Class I Antigen Presentation Machinery to Treat Cancer, Infections and Age-Related Diseases
    Priyanka Shailendra Rana, James John Ignatz-Hoover, James Joseph Driscoll · 2023 · Cancers
20. Oncolytic adenovirus in treating malignant ascites: A phase II trial and longitudinal single-cell study
    Yalei Zhang, Ling Qian, Kun Chen, Sijia Gu, Zhiqiang Meng, Jia Wang, Li Ye, Peng Wang · 2024 · Molecular Therapy
21. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review
    Wouter Ouwerkerk, Mirjam van den Berg, Sanne van der Niet, Jacqueline Limpens, Rosalie M. Luiten · 2019 · Melanoma Research
22. TCR sequencing analysis of cancer tissues and tumor draining lymph nodes in colorectal cancer patients
    Tatsuo Matsuda, Eisaku Miyauchi, Yu-Wen Hsu, Satoshi Nagayama, Kazuma Kiyotani, Makda Getachew Zewde, Jae‐Hyun Park, Taigo Kato, Makiko Harada, Shimpei Matsui et al. · 2019 · OncoImmunology
23. Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma
    Rohit Thakur, Jonathan P. Laye, Martin Lauss, Joey Mark S. Diaz, Sally Jane O'Shea, Joanna Poźniak, Anastasia Filia, Mark Harland, Joanne Gascoyne, Juliette A. Randerson‐Moor et al. · 2019 · Clinical Cancer Research
24. Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib
    Yanhong Shang, Xiaofang Li, Weiwei Liu, Xiaoliang Shi, S. H. Yuan, Ran Huo, Guotao Fang, Xiao Han, Jingnan Zhang, Kunjie Wang et al. · 2020 · Scientific Reports
25. Transcriptomics based multi-dimensional characterization and drug screen in esophageal squamous cell carcinoma
    Yin Li, Fengkai Xu, Fanghua Chen, Yiwei Chen, Di Ge, Shu Zhang, Chunlai Lu · 2021 · EBioMedicine
26. Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy
    Yun Gu, Puran Zhang, Jieti Wang, Chao Lin, Hao Liu, He Li, Hongyong He, Ruochen Li, Heng Zhang, Weijuan Zhang · 2022 · Cancer Immunology Immunotherapy
27. B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma
    Johannes Griss, Wolfgang Michael Bauer, Christine Wagner, Margarita Maurer‐Granofszky, Martin Simon, Minyi Chen, Peter Steinberger, Katharina Grabmeier‐Pfistershammer, Florian Roka, Thomas Penz et al. · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
28. New evaluation of the tumor immune microenvironment of non-small cell lung cancer and its association with prognosis
    Shuichi Shinohara, Yusuke Takahashi, Hiroyasu Komuro, Takuya Matsui, Yusuke Sugita, Ayako Demachi‐Okamura, Daisuke Muraoka, Hirotomo Takahara, Takeo Nakada, Noriaki Sakakura et al. · 2022 · Journal for ImmunoTherapy of Cancer
29. Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
    Avinash D Sahu, Xiaoman Wang, Phillip B. Munson, Jan P.G. Klomp, Xiaoqing Wang, Shengqing Stan Gu, Ya Han, Gege Qian, Phillip B. Nicol, Zexian Zeng et al. · 2023 · Cancer Discovery
30. Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
    Ben Umiker, Yasmin Hashambhoy-Ramsay, Jeff Smith, Tanzila Rahman, Amy Mueller, Rachel Davidson, Christina Meyer, Gayatri Patankar, Mohammad Murshid Alam, Sarah Jaffe et al. · 2023 · Molecular Cancer Therapeutics
31. Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-γ signalling
    Long Cao, Heng Lu, Mohammed Soutto, Nadeem Sidiq Bhat, Zheng Chen, Dunfa Peng, Ahmed R. Gomaa, Jiabin Wang, Jian Wei Xie, Ping Li et al. · 2023 · Gut
32. Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells
    Narendiran Rajasekaran, Xiaoguang Wang, Sruthi Ravindranathan, Daniel J. Chin, Su-Yi Tseng, Scott L. Klakamp, Kate Widmann, Varun N. Kapoor, Vladimir S. Vexler, Patricia Keegan et al. · 2024 · Cancer Immunology Immunotherapy
33. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
    Nikhil I. Khushalani, Patrick Alexander Ott, Robert Louis Ferris, Tina Cascone, Dirk Schadendorf, Dung Thi Le, Manish R. Sharma, Fabrice Barlési, William Howard Sharfman, Jason J. Luke et al. · 2024 · Journal for ImmunoTherapy of Cancer
34. Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial
    Kelly N. Fitzgerald, Chung‐Han Lee, Martin Henner Voss, Maria Isabel Carlo, Andrea Knežević, Laura Peralta, Ying‐Bei Chen, Robert A. Lefkowitz, Neil J. Shah, Colette Ngozi Owens et al. · 2024 · European Urology
35. CAR-T cell combination therapies in hematologic malignancies
    Delian Zhou, Xiaojian Zhu, Yi Qun Xiao · 2024 · Experimental Hematology and Oncology
36. Intratumoral mycobiome heterogeneity influences the tumor microenvironment and immunotherapy outcomes in renal cell carcinoma
    Weiming Mou, Zhixing Deng, Lingxuan Zhu, Aimin Jiang, Anqi Lin, Liling Xu, Gengwen Deng, Hongsen Huang, Zeji Guo, Bo Zhu et al. · 2025 · Science Advances
37. Melanoma-Secreted Lysosomes Trigger Monocyte-Derived Dendritic Cell Apoptosis and Limit Cancer Immunotherapy
    Nadine Santana-Magal, Leen Farhat-Younis, Amit Gutwillig, Annette Gleiberman, Diana Rasoulouniriana, Lior Tal, Dvir Netanely, Ron Shamir A, Rachel Blau, Meora Feinmesser et al. · 2020 · Cancer Research
38. Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge
    Ying Yang, Yongfeng Yu, Shun Lü · 2020 · Science China Life Sciences
39. Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC
    Wei Chong, Zhe Wang, Liang Shang, Shengtao Jia, Jin Liu, Zhen Fang, Fengying Du, Hao Wu, Yang Liu, Yang Chen et al. · 2020 · Molecular Therapy — Nucleic Acids
40. Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma
    Christopher G. Wood, James E. Ferguson, Joel S. Parker, Dominic T. Moore, Jennifer G. Whisenant, Susan J. Maygarden, Eric Wallen, William Y. Kim, Mathew I. Milowsky, Kathryn Eby Beckermann et al. · 2020 · JCI Insight
41. Investigating Mechanisms of Response or Resistance to Immune Checkpoint Inhibitors by Analyzing Cell-Cell Communications in Tumors Before and After Programmed Cell Death-1 (PD-1) Targeted Therapy: An Integrative Analysis Using Single-cell RNA and Bulk-RNA Sequencing Data
    Yiquan Jiang, Zixian Wang, Ming Zhong, Lujun Shen, Xue Han, Xuxiazi Zou, Xin-Yi Liu, Yi-Nan Deng, Yang Yang, Guihua Chen et al. · 2021 · OncoImmunology
42. Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy
    Martin Thelen, Kerstin Wennhold, Jonas M. Lehmann, Maria Alejandra Garcia-Marquez, Sebastian Klein, Elena Kochen, Philipp Lohneis, Axel Lechner, Svenja Wagener‐Ryczek, Patrick Sven Plum et al. · 2021 · npj Precision Oncology
43. Metabolic Molecule PLA2G2D Is a Potential Prognostic Biomarker Correlating With Immune Cell Infiltration and the Expression of Immune Checkpoint Genes in Cervical Squamous Cell Carcinoma
    Hong Liu, Ruiyi Xu, Chun Gao, Tong Zhu, Li‐Ting Liu, Yifan Yang, Haihong Zeng, Yafei Huang, Hui Wang · 2021 · Frontiers in Oncology
44. Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies
    Pınar Ataca Atilla, Erden Atilla · 2022 · Translational Oncology
45. Deep learning identifies a T-cell exhaustion-dependent transcriptional signature for predicting clinical outcomes and response to immune checkpoint blockade
    Zicheng Zhang, Hongyan Chen, Dongxue Yan, Lu Chen, Jie Sun, Meng Zhou · 2023 · Oncogenesis
46. DNAJA2 deficiency activates cGAS-STING pathway via the induction of aberrant mitosis and chromosome instability
    Yaping Huang, Changzheng Lu, Hanzhi Wang, Liya Gu, Yang‐Xin Fu, Guo‐Min Li · 2023 · Nature Communications
47. Predicting patient outcomes after treatment with immune checkpoint blockade: A review of biomarkers derived from diverse data modalities
    Yang Liu, Jennifer Altreuter, Sudheshna Bodapati, Simona Cristea, Cheryl J. Wong, Catherine J. Wu, Franziska Michor · 2023 · Cell Genomics
48. Long‐term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma
    Naoya Yamazaki, Yoshio Kiyohara, Hisashi Uhara, Jiro Uehara, Yasuhiro Fujisawa, Tatsuya Takenouchi, Masaki Otsuka, Hiroshi Uchi, Hironobu Ihn, Masahiro Hatsumichi et al. · 2019 · Cancer Science
49. The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients
    Arjun Khunger, Julie A. Rytlewski, Paul Fields, Erik C. Yusko, Ahmad A. Tarhini · 2019 · OncoImmunology
50. Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma
    Elena Galvani, Piyushkumar A. Mundra, Sara Valpione, Pablo Luis García-Martínez, Matthew Smith, Jonathan Greenall, Rohit Thakur, Beth Ann Helmink, Miles Cameron Andrews, Louis Boon et al. · 2020 · Nature Communications
51. Advances in theranostic biomarkers for tumor immunotherapy
    Audrey Bellesœur, Nouritza Torossian, Sebastián Amigorena, Emanuela Romano · 2020 · Current Opinion in Chemical Biology
52. Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect
    Xue Li Bai, Keith T. Flaherty · 2020 · British Journal of Dermatology
53. Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee
    Brian Gastman, Piyush Kumar Agarwal, Adam Berger, Genevieve Marie Boland, Stephen Broderick, Lisa Helene Butterfield, David R. Byrd, Peter Edward Fecci, Robert Louis Ferris, Yuman Fong et al. · 2020 · Journal for ImmunoTherapy of Cancer
54. Revealing Clonal Responses of Tumor-Reactive T-Cells Through T Cell Receptor Repertoire Analysis
    Hiroyasu Aoki, Shigeyuki Shichino, Kouji Matsushima, Satoshi Ueha · 2022 · Frontiers in Immunology
55. Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
    Michael Kuske, Maximilian Haist, Thomas Jung, Stephan Grabbe, Matthias Bros · 2022 · Cancers
56. Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)
    Rick D. Vavolizza, Gina R. Petroni, Ileana Soto Mauldin, Kimberly A. Chianese‐Bullock, Walter C. Olson, Kelly T. Smith, Lynn Thacher Dengel, Kathleen Haden, William W. Grosh, Varinder Kaur et al. · 2022 · Journal for ImmunoTherapy of Cancer
57. Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance
    Jamaal L. James, Brandie C. Taylor, Margaret L. Axelrod, Xiaopeng Sun, Lindsey N. Guerin, Paula I. González Ericsson, Yu Wang, Violeta M. Sanchez, Catherine C. Fahey, Melinda E. Sanders et al. · 2023 · Journal for ImmunoTherapy of Cancer
58. Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model
    Kun Chan Zheng, Youlong Hai, Hongqi Chen, Yukun Zhang, Xiaoyong Hu, Kai Ni · 2024 · Journal of Translational Medicine
59. An iron-rich subset of macrophages promotes tumor growth through a Bach1-Ednrb axis
    Ian Wesley Folkert, William A. Molina Arocho, Tsun Ki Jerrick To, Samir Devalaraja, Irene S. Molina, Jason Shoush, Hesham Mohei, Li Zhai, Md. Naushad Akhtar, Veena Kochat et al. · 2024 · The Journal of Experimental Medicine
60. Pretrained transformers applied to clinical studies improve predictions of treatment efficacy and associated biomarkers
    2025
61. Circulating CD8+ T-cell repertoires reveal the biological characteristics of tumors and clinical responses to chemotherapy in breast cancer patients
    Kai-Rong Lin, Danmei Pang, Yabin Jin, Qian Hu, Ying-ming Pan, Jin‐Huan Cui, Xiangping Chen, Yin-Xin Lin, Xiaofan Mao, Haibo Duan et al. · 2018 · Cancer Immunology Immunotherapy
62. Acquired resistance to immunotherapy in MMR-D pancreatic cancer
    Zishuo Ian Hu, Matthew David Hellmann, Jedd D. Wolchok, Monika Vyas, Jinru Shia, Zsofia Kinga Stadler, Luis Alberto Diaz, Eileen Mary O'Reilly · 2018 · Journal for ImmunoTherapy of Cancer
63. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab
    Luciana Lorena Molinero, Yijin Li, Ching‐Wei Chang, Sophia Lisette Maund, Maureen Berg, Jeanne Harrison, Marcella Fassò, Carol Elaine O'Hear, Priti S. Hegde, Leisha A. Emens · 2019 · Journal for ImmunoTherapy of Cancer
64. SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
    Siwen Hu‐Lieskovan, Srabani Bhaumik, Kavita M. Dhodapkar, Jean‐Charles Grivel, Sumati V. Gupta, Brent Allen Hanks, Sylvia Janetzki, Thomas O. Kleen, Yoshinobu Koguchi, Amanda W. Lund et al. · 2020 · Journal for ImmunoTherapy of Cancer
65. Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma
    Mattia Garutti, Serena Bonin, Silvia Buriolla, Elisa Bertoli, Maria Antonietta Pizzichetta, Iris Zalaudek, Fabio Puglisi · 2021 · Cancers
66. Immune and stromal scoring system associated with tumor microenvironment and prognosis: a gene-based multi-cancer analysis
    Zihang Zeng, Jiali Li, Jian‐Guo Zhang, Yangyi Li, Xingyu Liu, Jiarui Chen, Zhengrong Huang, Qiuji Wu, Yan Qing Gong, Conghua Xie · 2021 · Journal of Translational Medicine
67. Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers
    Daniel James McGrail, Patrick Glen Pilie, Hui Dai, Truong Lam, Yulong Liang, Leonie Voorwerk, Marleen Kok, Xiang H.-F. Zhang, Jeffrey M. Rosen, Amy B. Heimberger et al. · 2021 · Science Translational Medicine
68. Identification and Validation in a Novel Quantification System of Ferroptosis Patterns for the Prediction of Prognosis and Immunotherapy Response in Left- and Right-Sided Colon Cancer
    Hengchun Zhang, Shen-Hui Deng, Yanan Pi, Junnan Guo, Hua Xi, Xin Shi, Xue-Fei Yang, Bomiao Zhang, Weinan Xue, Binbin Cui et al. · 2022 · Frontiers in Immunology
69. Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
    Andrew Patterson, Noam Auslander · 2022 · Nature Communications
70. Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma
    Zhiyong Cai, You'e He, Zheng-Zheng Yu, Jiao Hu, Zicheng Xiao, Xiongbing Zu, Zhenghao Li, Huihuang Li · 2022 · Frontiers in Immunology
71. MHC II immunogenicity shapes the neoepitope landscape in human tumors
    Jeong Yeon Kim, Hongui Cha, Kyeonghui Kim, Changhwan Sung, Jinhyeon An, Hyoeun Bang, Hyungjoo Kim, Jin Ok Yang, Suhwan Chang, Incheol Shin et al. · 2023 · Nature Genetics
72. CD200 + cytotoxic T lymphocytes in the tumor microenvironment are crucial for efficacious anti–PD-1/PD-L1 therapy
    Xinxin Wang, Haoran Zha, Wei Wu, Ting Yuan, Shuanglong Xie, Zheng Jin, Haixia Long, Fei Yang, Zhongyu Wang, Anmei Zhang et al. · 2023 · Science Translational Medicine
73. An adverse tumor-protective effect of IDO1 inhibition
    Juliana C.N. Kenski, Xinyao Huang, David W. Vredevoogd, Beaunelle de Bruijn, Joleen J.H. Traets, Sofia Ibáñez‐Molero, Sebastiaan M. Schieven, Alex v. Vliet, Oscar Krijgsman, Thomas Kuilman et al. · 2023 · Cell Reports Medicine
74. Approaches for single-cell RNA sequencing across tissues and cell types
    Pooja Sant, Karsten Rippe, Jan‐Philipp Mallm · 2023 · Transcription
75. Enhancing Cancer Chemo‐Immunotherapy: Innovative Approaches for Overcoming Immunosuppression by Functional Nanomaterials
    Jingjing Wang, Li Li, Zhi Ping Xu · 2023 · Small Methods
76. Robust identification of perturbed cell types in single-cell RNA-seq data
    Phillip B. Nicol, Danielle Paulson, Gege Qian, X. Shirley Liu, Rafael A. Irizarry, Avinash D Sahu · 2024 · Nature Communications
77. Big Data Approaches for Modeling Response and Resistance to Cancer Drugs
    Peng Jiang, William R. Sellers, X. Shirley Liu · 2018 · Annual Review of Biomedical Data Science
78. Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies
    Martin Smoragiewicz, Jan Bogaerts, Emiliano Calvo, Aurélien Marabelle, A. Perrone, Lesley Seymour, A. Shalabi, Lillian L. Siu, Josep M. Tabernero, Giuseppe Giaccone et al. · 2018 · Annals of Oncology
79. The “-OMICS” facet of melanoma: Heterogeneity of genomic, proteomic and metabolomic biomarkers
    Douglas MacArthur Donnelly, Phyu P. Aung, George Jour · 2019 · Seminars in Cancer Biology
80. NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images
    Virginia Liberini, Annapaola Mariniello, Luisella Righi, Martina Capozza, Marco Donatello Delcuratolo, Enzo Terreno, Mohsen Farsad, Marco Volante, Silvia Novello, Désirèe Deandreis · 2021 · Cancers
81. Urinary detection of early responses to checkpoint blockade and of resistance to it via protease-cleaved antibody-conjugated sensors
    Quoc D. Mac, Anirudh Sivakumar, Hathaichanok Phuengkham, Congmin Xu, James R. Bowen, Fang‐Yi Su, Samuel Z. Stentz, Hyoungjun Sim, Adrian M. Harris, Tonia T. Li et al. · 2022 · Nature Biomedical Engineering
82. Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation
    Lin Zhu, Xinwei Kuang, Guanxiong Zhang, Long Liang, Dandan Liu, Bin Hu, Zuozhong Xie, Hui Li, Hong Liu, Mao Ye et al. · 2022 · Journal for ImmunoTherapy of Cancer
83. Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy
    Miles Cameron Andrews, Alexandre Reuben, Vancheswaran Gopalakrishnan, Jennifer Ann Wargo · 2018 · Frontiers in Immunology
84. Biomechanics of T Cell Dysfunctions in Chronic Diseases
    Sachith D. Gunasinghe, Newton G. Peres, Jesse Goyette, Katharina Gaus · 2021 · Frontiers in Immunology
85. Acarbose enhances the efficacy of immunotherapy against solid tumours by modulating the gut microbiota
    Shilong Zhang, Xin Wang, Qing-Qing Cai, Chen Chen, Zheng-Yan Zhang, Yayun Xu, Mengxuan Yang, Qing-An Jia, Yan Wang, Zhi-ming Wang · 2024 · Nature Metabolism
86. Tertiary Lymphoid Structures are Linked to Enhanced Antitumor Immunity and Better Prognosis in Muscle‐Invasive Bladder Cancer
    Jiaxing Lin, Shan Jiang, Baoqiang Chen, Yiqing Du, Caipeng Qin, Yuxuan Song, Yun Peng, Mengting Ding, Jilin Wu, Yihan Lin et al. · 2024 · Advanced Science
87. Cancer Evolution during Immunotherapy
    Miles Cameron Andrews, Jennifer Ann Wargo · 2017 · Cell
88. TCR Repertoire Analysis Reveals Mobilization of Novel CD8+ T Cell Clones Into the Cancer-Immunity Cycle Following Anti-CD4 Antibody Administration
    Hiroyasu Aoki, Satoshi Ueha, Shigeyuki Shichino, Haru Ogiwara, Shin-ichi Hashimoto, Kazuhiro Kakimi, Satoru Ito, Kouji Matsushima · 2019 · Frontiers in Immunology
89. WISP1 is associated to advanced disease, EMT and an inflamed tumor microenvironment in multiple solid tumors
    Pierre-Olivier Gaudreau, Sylvie Clairefond, Caleb A. Class, Pierre-Luc Boulay, Pavel Chrobák, Bertrand Allard, Féryel Azzi, Sandra Pommey, Kim-Anh Do, Fred Saad C et al. · 2019 · OncoImmunology
90. Differential gene expression of tumor-infiltrating CD8 + T cells in advanced versus early-stage colorectal cancer and identification of a gene signature of poor prognosis
    Reem Saleh, Varun Sasidharan Nair, Salman M. Toor, Rowaida Ziad Taha, Khaled Murshed, Mahmood Al‐Dhaheri, Mahwish Khawar, Mahir Abdulla Petkar, Mohamed Abu Nada, Fares Al‐Ejeh et al. · 2020 · Journal for ImmunoTherapy of Cancer
91. DGKA Mediates Resistance to PD-1 Blockade
    Lingyi Fu, Sen Li, Weiwei Xiao, Kuai Yu, Shuo Li, Sujing Yuan, Jianfei Shen, Xingjun Dong, Ziqian Fang, Jianeng Zhang et al. · 2021 · Cancer Immunology Research
92. Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotype
    Lea Jessica Albrecht, A. Hoewner, Klaus Griewank, Smiths Lueong, Nils v. Neuhoff, Péter Horn, Antje Sucker, Annette Paschen, Elisabeth Livingstone, Selma Ugurel et al. · 2022 · Clinical and Translational Medicine
93. Cancer-associated fibroblasts-derived exosomes from chemoresistant patients regulate cisplatin resistance and angiogenesis by delivering VEGFA in colorectal cancer
    Yuanyuan Shi, Hua Zhu, Hang Jiang, Hongqin Yue, Fang Yuan, Fu‐Sheng Wang · 2022 · Anti-Cancer Drugs
94. Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers
    Marco Russano, Giulia La Cava, Alessio Cortellini, Fabrizio Citarella, Alessandro Galletti, Giuseppina Rita Di Fazio, Valentina Santo, Leonardo Brunetti, Alessia Vendittelli, Iacopo Fioroni et al. · 2023 · Current Oncology
95. The role of IFN-γ-signalling in response to immune checkpoint blockade therapy
    Chun Wai Wong, Yang Huang, Adam F. L. Hurlstone · 2023 · Essays in Biochemistry
96. Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy
    Maria Luigia Carbone, Alessia Capone, Marika Guercio, Sofia Reddel, Domenico Alessandro Silvestris, Daniela Lulli, Carmela Ramondino, Daniele Peluso, Concetta Quintarelli, Elisabetta Volpe et al. · 2023 · Frontiers in Immunology
97. Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy
    Andrea Ziblat, Brendan L. Horton, Emily F. Higgs, Ken Hatogai, Anna Martinez, Jason W. Shapiro, Danny EC Kim, Yuanyuan Zha, Randy F. Sweis, Thomas Frank Gajewski · 2024 · Cell Reports
98. Non-invasive profiling of the tumour microenvironment with spatial ecotypes
    Wubing Zhang, Erin L. Brown, Abul Usmani, Noah J. Earland, Minji Kang, Chibuzor Olelewe, Anushka Viswanathan, Pradeep S. Chauhan, Chloé Beate Steen, Hyun Soo Jeon et al. · 2026 · Nature
99. Detecting Immune Response to Therapies Targeting PDL1 and BRAF by Using Ferumoxytol MRI and Macrin in Anaplastic Thyroid Cancer
    Thomas S.C. Ng, Viswanath Gunda, Ran Li, Mark Prytyskach, Yoshiko Iwamoto, Rainer H. Köhler, Sareh Parangi, Ralph Weissleder, Miles Aaron Miller · 2020 · Radiology
100. Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy
     Shangqin Sun, Liwen Xu, Xinxin Zhang, Lin Pang, Zhilin Long, Chunyu Deng, Jiali Zhu, Shuting Zhou, Linyun Wan, Bo Pang et al. · 2021 · Cancers